Lenalidomide Capsule
Product Images NDC 69097-382

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 69097-382). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (A179bba1 61ac 42f6 Bbae Da9c1d830c40 01)

Chemical structure of lenalidomide, showing its molecular framework including an amino group, lactam rings, and carbonyl groups as typically depicted for the active pharmaceutical ingredient lenalidomide.*

FDA Label Image

1 (A179bba1 61ac 42f6 Bbae Da9c1d830c40 02)

A Kaplan-Meier survival curve chart showing progression-free survival probability over months for three treatment groups labeled Rd Continuous, Rd18, and MPT. The y-axis represents survival probability percentage from 0 to 100%, and the x-axis shows time in months from 0 to 60. The chart includes number of subjects at risk at various time points and hazard ratios with confidence intervals comparing the groups, along with a logrank p-value indicating statistical significance.*

FDA Label Image

2 (A179bba1 61ac 42f6 Bbae Da9c1d830c40 03)

A Kaplan-Meier survival curve depicting overall survival probability (%) over time in months for three treatment groups labeled Rd Continuous, Rd18, and MPT. The graph includes confidence intervals for hazard ratios comparing the treatments and shows the number of subjects at risk at various time points along the x-axis.*

FDA Label Image

3 (A179bba1 61ac 42f6 Bbae Da9c1d830c40 04)

A Kaplan-Meier plot comparing progression-free survival over months in subjects treated with lenalidomide versus placebo. The y-axis represents the proportion of subjects progression-free, ranging from 0 to 1. The lenalidomide group shows higher survival rates over time compared to the placebo group, with median progression-free survival times and hazard ratios annotated. A table below the graph indicates the number of subjects at risk at various time points for both groups.*

FDA Label Image

4 (A179bba1 61ac 42f6 Bbae Da9c1d830c40 05)

A Kaplan-Meier survival curve chart comparing progression-free survival probability over time (months) between lenalidomide and placebo groups. The y-axis represents survival probability, and the x-axis shows progression-free survival in months. The chart includes hazard ratio (HR) and median progression-free survival statistics with confidence intervals, along with numbers of subjects at risk for each group at specified time points.*

FDA Label Image

5 (A179bba1 61ac 42f6 Bbae Da9c1d830c40 06)

A Kaplan-Meier survival curve displaying time to progression in months for patients receiving lenalidomide plus dexamethasone versus placebo plus dexamethasone. The vertical axis shows the proportion of subjects, while the horizontal axis shows time to progression from 0 to 30 months. The curve for lenalidomide/dexamethasone demonstrates higher survival without progression compared to placebo/dexamethasone, with statistical data including hazard ratio and log-rank p-value noted.*

FDA Label Image

6 (A179bba1 61ac 42f6 Bbae Da9c1d830c40 07)

A Kaplan-Meier survival curve showing the proportion of subjects over time to progression (months) comparing two treatment groups: Lenalidomide/Dex and Placebo/Dex. The graph highlights a significant difference between the groups, with Lenalidomide/Dex showing a higher proportion of subjects without progression over time.*

FDA Label Image

Image-1 (A179bba1 61ac 42f6 Bbae Da9c1d830c40 08)

A Kaplan-Meier survival probability plot comparing progression-free survival over 48 months between two groups: one receiving rituximab plus lenalidomide and the other receiving rituximab plus placebo. The y-axis represents survival probability and the x-axis shows progression-free survival time in months. The graph includes numbers at risk for each group at various time points.*

FDA Label Image

Container-5mg-genvion (A179bba1 61ac 42f6 Bbae Da9c1d830c40 09)

Lenalidomide Capsules 5 mg packaging label from Cipla USA Inc. The label shows the product name with the strength prominently displayed, a warning about potential human birth defects, and the labeler's name Cipla. It states a package count of 28 capsules and includes storage instructions, manufacturer information, and a barcode.*

FDA Label Image

Container-10mg-genvion (A179bba1 61ac 42f6 Bbae Da9c1d830c40 10)

Label for Lenalidomide Capsules 10 mg oral capsules by Cipla USA Inc. The label includes a warning about potential for human birth defects, pharmacist dispensing instructions, and storage conditions. It shows a package size of 28 capsules and includes manufacturer information for Cipla Ltd. and Cipla USA Inc. A barcode is displayed on the right side.*

FDA Label Image

Container-15mg-genvion (A179bba1 61ac 42f6 Bbae Da9c1d830c40 11)

Lenalidomide Capsules 15 mg label for oral use by Cipla USA Inc. The label includes the drug name, strength 15 mg, a warning about potential human birth defects, a note for pharmacists to dispense the accompanying medication guide to each patient, and information about manufacturer and storage conditions. The package contains 21 capsules.*

FDA Label Image

Container-25mg-genvion (A179bba1 61ac 42f6 Bbae Da9c1d830c40 12)

Label for Lenalidomide Capsules 25 mg by Cipla USA Inc. The label includes a warning about potential human birth defects and instructions for pharmacists to dispense the accompanying Medication Guide. It states the package contains 21 capsules and provides storage information, manufacturer details, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.